1216 related articles for article (PubMed ID: 18774869)
41. Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.
Einarson TR; Maia-Lopes S; Goswami P; Bereza BG; Van Impe K
J Med Econ; 2016 Sep; 19(9):913-21. PubMed ID: 27124697
[TBL] [Abstract][Full Text] [Related]
42. [Cost-effectiveness study of olanzapine pamoate: Mirror-image analysis after one year].
Potaufeu J; Langrée B; Drapier D; Burgot G; Marie N
Encephale; 2019 Jun; 45(3):232-238. PubMed ID: 30579574
[TBL] [Abstract][Full Text] [Related]
43. The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden.
Willis M; Svensson M; Löthgren M; Eriksson B; Berntsson A; Persson U
Eur J Health Econ; 2010 Dec; 11(6):585-94. PubMed ID: 20084535
[TBL] [Abstract][Full Text] [Related]
44. Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness.
Keith S
Expert Rev Neurother; 2009 Jan; 9(1):9-31. PubMed ID: 19102665
[TBL] [Abstract][Full Text] [Related]
45. Cost analysis of risperidone long-acting injection in the treatment of schizophrenia and schizoaffective disorders in Hong Kong: an approach using generalised estimating equations.
Wu DB; Lee EH; Chung WS; Chow DP; Lee VW; Wong MC; Lee KK
Psychiatry Res; 2013 Dec; 210(3):745-50. PubMed ID: 24012164
[TBL] [Abstract][Full Text] [Related]
46. Cost-effectiveness of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA.
Augusto M; Greene M; Touya M; Sweeney SM; Waters H
J Comp Eff Res; 2018 Jul; 7(7):637-650. PubMed ID: 29694244
[TBL] [Abstract][Full Text] [Related]
47. Health service utilization and medical costs among patients with schizophrenia receiving long-acting injectable risperidone versus oral risperidone: a nationwide retrospective matched cohort study in Taiwan.
Fan SJ; Lu N; Chang HC; Tang CH; Huang KC
Int Clin Psychopharmacol; 2018 Jul; 33(4):204-212. PubMed ID: 29489495
[TBL] [Abstract][Full Text] [Related]
48. The cost-effectiveness of risperidone long-acting injection in the treatment of schizophrenia.
Chue P; Chue J
Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):259-69. PubMed ID: 22812548
[TBL] [Abstract][Full Text] [Related]
49. Cost effectiveness of long-acting risperidone in Sweden.
Hensen M; Heeg B; Löthgren M; van Hout B
Appl Health Econ Health Policy; 2010; 8(5):327-41. PubMed ID: 20804225
[TBL] [Abstract][Full Text] [Related]
50. The impact of treatment with risperidone long-acting injection on the Belgian healthcare system: results from a budget impact model.
Annemans L; Eijgelshoven I; Smet A; Jacobs A; Bergman G
Acta Clin Belg; 2012; 67(2):108-19. PubMed ID: 22712166
[TBL] [Abstract][Full Text] [Related]
51. Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia.
Leatherman SM; Liang MH; Krystal JH; Lew RA; Valley D; Thwin SS; Rosenheck RA;
J Nerv Ment Dis; 2014 Jan; 202(1):13-7. PubMed ID: 24375206
[TBL] [Abstract][Full Text] [Related]
52. Hospitalizations and economic analysis in psychotic patients with paliperidone palmitate long-acting injection.
Mesones-Peral JE; Gurillo-Muñoz P; Sánchez-Sicilia MP; Miller A; Griñant-Fernández A
Rev Psiquiatr Salud Ment; 2017; 10(1):33-37. PubMed ID: 27053545
[TBL] [Abstract][Full Text] [Related]
53. Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy.
Yan T; Greene M; Chang E; Houle CR; Waters HC; Tarbox MH; Broder MS
Clin Ther; 2020 Jan; 42(1):77-93. PubMed ID: 31928831
[TBL] [Abstract][Full Text] [Related]
54. Cost-effectiveness analysis of schizophrenia relapse prevention : an economic evaluation of the ZEUS (Ziprasidone-Extended-Use-In-Schizophrenia) study in Spain.
Bernardo M; Ramón Azanza J; Rubio-Terrés C; Rejas J
Clin Drug Investig; 2006; 26(8):447-57. PubMed ID: 17163277
[TBL] [Abstract][Full Text] [Related]
55. Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands.
Einarson TR; Bereza BG; Tedouri F; Van Impe K; Denee TR; Dries PJT
J Med Econ; 2017 Nov; 20(11):1187-1199. PubMed ID: 28762843
[TBL] [Abstract][Full Text] [Related]
56. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study.
Nielsen J; Jensen SO; Friis RB; Valentin JB; Correll CU
Schizophr Bull; 2015 May; 41(3):627-36. PubMed ID: 25180312
[TBL] [Abstract][Full Text] [Related]
57. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
58. Explicit review of risperidone long-acting injection prescribing practice.
Wheeler A; Vanderpyl J; Carswell C; Stojkovic M; Robinson E
J Clin Pharm Ther; 2011 Dec; 36(6):651-63. PubMed ID: 22023342
[TBL] [Abstract][Full Text] [Related]
59. Hospitalization resource utilization and costs among Medicaid insured patients with schizophrenia with different treatment durations of long-acting injectable antipsychotic therapy.
Bera R; Offord S; Zubek D; Lau G; Lin J; Karson C
J Clin Psychopharmacol; 2014 Feb; 34(1):30-5. PubMed ID: 24135840
[TBL] [Abstract][Full Text] [Related]
60. Annual cost of relapses and relapse-related hospitalizations in adults with schizophrenia: results from a 12-month, double-blind, comparative study of lurasidone vs quetiapine extended-release.
Rajagopalan K; O'Day K; Meyer K; Pikalov A; Loebel A
J Med Econ; 2013 Aug; 16(8):987-96. PubMed ID: 23742620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
